A detailed history of Ameriprise Financial Inc transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Ameriprise Financial Inc holds 1,347,680 shares of CERE stock, worth $0. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,347,680
Previous 562,773 139.47%
Holding current value
$0
Previous $23.8 Million 131.65%
% of portfolio
0.02%
Previous 0.01%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$38.96 - $42.75 $30.6 Million - $33.6 Million
784,907 Added 139.47%
1,347,680 $55.1 Million
Q1 2024

May 15, 2024

BUY
$40.88 - $43.27 $22.8 Million - $24.1 Million
557,340 Added 10258.42%
562,773 $23.8 Million
Q4 2023

Feb 14, 2024

BUY
$20.27 - $42.44 $110,126 - $230,576
5,433 New
5,433 $230,000

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.